Author | Ichihara, Eiki| Matsuoka, Junji| Takigawa, Nagio| Matsuzaki, Takashi| Katsui, Kuniaki| Kiura, Katsuyuki| Tanimoto, Mitsune| |
---|---|
Published Date | 2009-12-01 |
Publication Title | 岡山医学会雑誌 |
Volume | volume121 |
Issue | issue3 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/32866 |
---|---|
FullText URL | fulltext.pdf |
Author | Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune| |
Abstract | <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were <70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p> |
Keywords | cisplatin docetaxel irinotecan triplet chemotherapy gefitinib |
Amo Type | Original Article |
Published Date | 2010-02 |
Publication Title | Acta Medica Okayama |
Volume | volume64 |
Issue | issue1 |
Publisher | Okayama University Medical School |
Start Page | 33 |
End Page | 37 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | 英語 |
File Version | publisher |
Refereed | True |
PubMed ID | 20200582 |
Web of Science KeyUT | 000274868300005 |
JaLCDOI | 10.18926/AMO/40503 |
---|---|
FullText URL | 64_5_285.pdf |
Author | Nishimori, Hisakazu| Takahashi, Shunji| Kiura, Katsuyuki| Ennishi, Daisuke| Kobayashi, Takayuki| Sano, Koji| Shinozaki, Eiji| Yokoyama, Masahiro| Mishima, Yuko| Terui, Yasuhito| Chin, Keisho| Mizunuma, Nobuyuki| Ito, Yoshinori| Nishimura, Seiichiro| Takeuchi, Kengo| Ishikawa, Yuichi| Oguchi, Masahiko| Tanimoto, Mitsune| Hatake, Kiyohiko| |
Abstract | We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer. |
Keywords | cancer of unknown primary site (CUP) cisplatin docetaxel prognosis |
Amo Type | Original Article |
Published Date | 2010-10 |
Publication Title | Acta Medica Okayama |
Volume | volume64 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 285 |
End Page | 291 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | 英語 |
Copyright Holders | CopyrightⒸ 2010 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 20975761 |
Web of Science KeyUT | 000283563300003 |
Author | Ichihara, Eiki| Ohashi, Kadoaki| Takigawa, Nagio| Osawa, Masahiro| Ogino, Atsuko| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2011-04-01 |
Publication Title | 岡山医学会雑誌 |
Volume | volume123 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/46851 |
---|---|
FullText URL | 65_4_259.pdf |
Author | Ogata, Yoshiko| Aoe, Keisuke| Hiraki, Akio| Murakami, Kazuo| Kishino, Daizo| Chikamori, Kenichi| Maeda, Tadashi| Ueoka, Hiroshi| Kiura, Katsuyuki| Tanimoto, Mitsune| |
Abstract | The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a country with intermediate incidence of tuberculosis (TB). We retrospectively reviewed the clinical records of 435 patients with pleural effusion and investigated their pleural ADA levels as determined by an auto analyzer. ROC analysis was also performed. The study included patients with MPE (n=188), TPE (n=124), benign nontuberculous pleural effusion (n=94), and pleural effusion of unknown etiology (n=29). The median ADA level in the TPE group was 70.8U/L, which was significantly higher than that in any other groups (p<0.05). The area under the curve (AUC) in ROC analysis was 0.895. With a cut-off level for ADA of 36U/L, the sensitivity, specificity, positive predictive value, and negative predictive value were 85.5%, 86.5%, 69.7%, and 93.6%, respectively. As many as 9% of patients with lung cancer and 15% of those with mesothelioma were false-positive with this ADA cutoff setting. Although the ADA activity in pleural fluid can help in the diagnosis of TPE, it should be noted that some cases of lung cancer or mesothelioma show high ADA activity in geographical regions with intermediate incidence of TB, in contrast to high prevalence areas. |
Keywords | pleural effusion adenosine deaminase tuberculosis lung cancer mesothelioma |
Amo Type | Original Article |
Published Date | 2011-08 |
Publication Title | Acta Medica Okayama |
Volume | volume65 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 259 |
End Page | 263 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | 英語 |
Copyright Holders | CopyrightⒸ 2011 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 21860532 |
Web of Science KeyUT | 000294236700006 |
Author | Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2011-09 |
Publication Title | Molecular Cancer Therapeutics |
Volume | volume10 |
Issue | issue9 |
Content Type | Journal Article |
Author | Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune| |
---|---|
Published Date | 2011-10 |
Publication Title | Lung Cancer |
Volume | volume74 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/47260 |
---|---|
FullText URL | 65_6_353.pdf |
Author | Ichihara, Eiki| Kiura, Katsuyuki| Tanimoto, Mitsune| |
Abstract | Angiogenesis is an essential process in tumor growth. The concept of angiogenesis, when proposed by Folksman in 1971, had a great impact on cancer research and therapy, as the survival and proliferation of cancer depend on angiogenesis, which could be a target of cancer therapy. In subsequent decades, numerous antiangiogenic agents were developed, and some of them have been applied clinically. However, angiogenesis includes a complex and multistep process that has not been sufficiently elucidated. In this review, we focus on signaling pathways related with tumor angiogenesis and several antiangiogenic agents approved by the United States Food and Drug Administration or under investigation. |
Keywords | angiogenesis cancer |
Amo Type | Review |
Published Date | 2011-12 |
Publication Title | Acta Medica Okayama |
Volume | volume65 |
Issue | issue6 |
Publisher | Okayama University Medical School |
Start Page | 353 |
End Page | 362 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | 英語 |
Copyright Holders | CopyrightⒸ 2011 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 22189475 |
Web of Science KeyUT | 000298516900001 |
Author | Taniguchi, Akihiko| Miyahara, Nobuaki| Nakahara, Atsushi| Takata, Saburo| Sakugawa, Ryo| Nagano, Osamu| Tanimoto, Yasushi| Kanehiro, Arihiko| Kiura, Katsuyuki| Ujike, Yoshito| Tanimoto, Mitsune| |
---|---|
Published Date | 2011-12-01 |
Publication Title | 岡山医学会雑誌 |
Volume | volume123 |
Issue | issue3 |
Content Type | Journal Article |
Author | Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro| |
---|---|
Published Date | 2012-04 |
Publication Title | Lung Cancer |
Volume | volume76 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/48564 |
---|---|
FullText URL | 66_3_245.pdf |
Author | Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
Abstract | Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6). |
Keywords | cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention |
Amo Type | Original Article |
Published Date | 2012-06 |
Publication Title | Acta Medica Okayama |
Volume | volume66 |
Issue | issue3 |
Publisher | Okayama University Medical School |
Start Page | 245 |
End Page | 251 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | 英語 |
Copyright Holders | CopyrightⒸ 2012 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 22729105 |
Web of Science KeyUT | 000305669700008 |
Author | Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro| |
---|---|
Published Date | 2012-07 |
Publication Title | Lung Cancer |
Volume | volume77 |
Issue | issue1 |
Content Type | Journal Article |
Author | Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2012-10 |
Publication Title | Cancer Science |
Volume | volume103 |
Issue | issue10 |
Content Type | Journal Article |
Author | Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2012-12-03 |
Publication Title | 岡山医学会雑誌 |
Volume | volume124 |
Issue | issue3 |
Content Type | Journal Article |
Author | Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2013-01 |
Publication Title | Cancer Science |
Volume | volume104 |
Issue | issue1 |
Content Type | Journal Article |
Author | Takeda, Hiromasa| Takigawa, Nagio| Ohashi, Kadoaki| Minami, Daisuke| Kataoka, Itaru| Ichihara, Eiki| Ochi, Nobuaki| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2013-02-15 |
Publication Title | Experimental Cell Research |
Volume | volume319 |
Issue | issue4 |
Content Type | Journal Article |
Author | Kiura, Katsuyuki| Tanimoto, Mitsune| |
---|---|
Published Date | 2013-04-01 |
Publication Title | 岡山医学会雑誌 |
Volume | volume125 |
Issue | issue1 |
Content Type | Journal Article |
Author | Ninomiya, Takashi| Takigawa, Nagio| Ichihara, Eiki| Ochi, Nobuaki| Murakami, Toshi| Honda, Yoshihiro| Kubo, Toshio| Minami, Daisuke| Kudo, Kenichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2013-05 |
Publication Title | Molecular Cancer Therapeutics |
Volume | volume12 |
Issue | issue5 |
Content Type | Journal Article |
Author | Kiura, Katsuyuki| |
---|---|
Published Date | 2013-08-01 |
Publication Title | 岡山医学会雑誌 |
Volume | volume125 |
Issue | issue2 |
Content Type | Journal Article |
Author | Hayakawa, Hiromi| Ichihara, Eiki| Ohashi, Kadoaki| Ninomiya, Takashi| Yasugi, Masayuki| Takata, Saburo| Sakai, Katsuya| Matsumoto, Kunio| Takigawa, Nagio| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2013-11 |
Publication Title | Cancer Science |
Volume | volume104 |
Issue | issue11 |
Content Type | Journal Article |